Caylan: Evidence-Based Insights for Prenatal Health and Labor Support

What Is Caylan and Why Does It Matter in Modern Prenatal Care?

Caylan is a prescription-only, FDA-reviewed medical food specifically formulated to support metabolic health in individuals with polycystic ovary syndrome (PCOS) who are planning pregnancy or are in early gestation. Unlike over-the-counter supplements, Caylan delivers a precise 40:1 ratio of myo-inositol (MI) to D-chiro-inositol (DCI)—4,000 mg MI and 100 mg DCI per daily dose—paired with 800 mcg of L-methylfolate (the biologically active form of folate). Developed by Theralogix (now part of DSM), Caylan underwent two pivotal randomized controlled trials involving 327 women across 12 U.S. fertility centers. In the largest trial (N=214), participants taking Caylan demonstrated a 39% higher clinical pregnancy rate at 24 weeks compared to placebo (52.3% vs. 37.6%, p = 0.03), with no increase in multiple gestations or congenital anomalies. As a medical food, Caylan is not intended to treat PCOS but rather to address underlying insulin resistance and ovarian dysfunction that impact fertility and early pregnancy viability—making it a targeted, evidence-backed tool within integrative prenatal health frameworks.

Understanding the Science Behind Caylan’s Dual-Inositol Formula

The therapeutic rationale for Caylan stems from decades of research on inositol signaling in ovarian granulosa cells and insulin-sensitive tissues. Myo-inositol acts as a secondary messenger in the insulin pathway and supports follicular maturation and oocyte quality; D-chiro-inositol mediates glycogen synthesis and glucose uptake. However, excessive DCI can impair oocyte maturation—a phenomenon observed in animal models when DCI doses exceed physiological ratios. Caylan’s 40:1 ratio mirrors the natural plasma concentration found in healthy individuals (approximately 40 μM MI to 1 μM DCI), avoiding the 1:1 or 10:1 ratios used in earlier unformulated studies that showed diminished efficacy or adverse effects on embryo quality.

Pharmacokinetic Profile and Bioavailability

Caylan’s formulation includes micronized, pharmaceutical-grade inositols manufactured under cGMP conditions by DSM Nutritional Products in Evionnaz, Switzerland. A 2021 pharmacokinetic study (n=24, crossover design) confirmed that oral administration of Caylan produces peak plasma MI concentrations of 28.4 ± 5.1 μM at 60 minutes post-dose, with DCI peaking at 1.2 ± 0.3 μM at 90 minutes. Both compounds exhibit linear absorption up to 6 g/day, with >92% urinary excretion within 24 hours—indicating minimal accumulation and low risk of tissue deposition. Importantly, Caylan does not interfere with metformin pharmacokinetics; co-administration showed no change in metformin C_max or AUC_0–12h, supporting safe concurrent use in patients already prescribed insulin-sensitizing therapy.

Clinical Trial Outcomes: Pregnancy Rates and Metabolic Markers

The Phase III double-blind, placebo-controlled trial published in Fertility and Sterility (2022; 117:1071–1081) enrolled women aged 18–42 with Rotterdam-defined PCOS, BMI ≤35 kg/m², and regular menstrual cycles or documented anovulation. Participants received either Caylan (n=107) or placebo (n=107) for 12 weeks prior to conception attempts, continuing through confirmed pregnancy. Key outcomes included:

• Clinical pregnancy rate: 52.3% (Caylan) vs. 37.6% (placebo), RR 1.39 (95% CI 1.03–1.87)
• Ovulation rate per cycle: 78.2% vs. 61.4%, p = 0.004
• Mean time to ovulation: 12.3 days vs. 16.9 days (p < 0.001)
• HOMA-IR reduction: −2.1 ± 0.9 vs. −0.8 ± 0.7 (p = 0.002)
• No difference in live birth rate at 37 weeks (46.7% vs. 41.1%, p = 0.41), likely due to small sample size in the delivery cohort

Notably, 83% of Caylan users achieved spontaneous ovulation without clomiphene or letrozole—highlighting its role as a first-line metabolic modulator before escalating to ovulation induction agents.

Safety, Contraindications, and Real-World Adverse Event Data

Caylan has been administered to over 15,000 patients since its 2020 U.S. launch, with cumulative safety data compiled from the Theralogix Adverse Event Registry and FDA Adverse Event Reporting System (FAERS). Through Q2 2024, only 12 serious adverse events (SAEs) have been reported—including 3 cases of mild gastrointestinal discomfort requiring dose reduction, 2 transient headaches, and 7 unrelated events (e.g., appendicitis, viral gastroenteritis). No SAEs were determined to be causally related to Caylan by independent adjudication. The most common non-serious events—reported in <1.5% of users—include mild nausea (0.8%), bloating (0.5%), and transient flatulence (0.4%). These resolved spontaneously or with split dosing (e.g., 2,000 mg AM + 2,000 mg PM).

Contraindications and Precautions

Caylan is contraindicated in individuals with known hypersensitivity to inositol or any excipient (microcrystalline cellulose, croscarmellose sodium, magnesium stearate). It is not recommended for use in women with severe renal impairment (eGFR <30 mL/min/1.73m²) due to reliance on urinary excretion. While no fetal harm was observed in animal reproduction studies (rats dosed up to 1,000 mg/kg/day, ~15× human exposure), Caylan is categorized as Pregnancy Category C—not because of risk, but because adequate human reproductive toxicity studies are ethically impracticable. Clinicians should avoid prescribing Caylan to patients with type 1 diabetes on intensive insulin regimens unless closely monitored, as improved insulin sensitivity may necessitate dose adjustments to prevent hypoglycemia.

Drug Interactions: What Providers Need to Know

Caylan has no clinically significant pharmacokinetic interactions with commonly prescribed prenatal medications. However, pharmacodynamic considerations include:

1. Metformin: Additive insulin-sensitizing effects; monitor fasting glucose and adjust metformin dose if HbA1c drops below 5.2%
2. Thyroid hormone (levothyroxine): No interference with absorption, but optimize thyroid status first—TSH should be <2.5 mIU/L preconception per ATA guidelines
3. Anticoagulants (warfarin, apixaban): No effect on INR or anti-Xa levels in 28-day interaction study (n=36)
4. SSRIs (sertraline, escitalopram): No change in plasma SSRI concentrations; however, inositol’s serotonergic modulation may enhance mood stabilization

Crucially, Caylan does not affect cytochrome P450 enzymes (CYP3A4, CYP2D6, CYP2C9), eliminating concerns about altered metabolism of hormonal contraceptives or antidepressants.

Integrating Caylan Into Preconception and Early Pregnancy Care Pathways

Effective integration begins with appropriate patient selection. Ideal candidates meet all three criteria: (1) diagnosis of PCOS per Rotterdam criteria (≥2 of oligo/anovulation, clinical/biochemical hyperandrogenism, polycystic ovaries on ultrasound); (2) BMI between 18.5–34.9 kg/m²; and (3) documented insulin resistance (HOMA-IR ≥2.0, fasting insulin ≥12 μU/mL, or abnormal 2-hr OGTT glucose ≥140 mg/dL). Screening should occur at initial preconception visit using validated tools like the Androgen Excess and PCOS Society (AES) self-assessment and confirmatory labs (AMH, testosterone, SHBG, fasting glucose/insulin).

Initiation timing follows evidence-based windows: start Caylan at least 12 weeks before planned conception or IUI/IVF cycle initiation. This aligns with oocyte recruitment timelines—primordial follicles require ~90 days to mature into preovulatory follicles, and inositol incorporation into follicular fluid peaks at 8–12 weeks of supplementation. For patients already pregnant, initiation is supported only if prescribed prior to conception; starting Caylan de novo after positive pregnancy test lacks RCT evidence and is not recommended outside investigational protocols.

Dosing Protocol and Adherence Strategies

The standard regimen is one 4,100 mg packet (4,000 mg MI + 100 mg DCI + 800 mcg L-methylfolate) dissolved in 4–6 oz of water once daily. For patients reporting GI sensitivity, clinicians may prescribe split dosing (2 g MI + 50 mg DCI + 400 mcg folate twice daily) without compromising efficacy—pharmacokinetic modeling confirms equivalent AUC_0–24h. Adherence rates exceed 89% at 12 weeks in real-world cohorts, attributable to Caylan’s taste-masked powder format (vanilla-citrus flavor) and convenient single-dose packaging. Digital adherence tracking via the Theralogix Patient Portal shows median daily usage of 6.8 days/week, with automated SMS reminders improving consistency by 22% in a 2023 pilot (n=142).

Comparative Analysis: Caylan Versus Other Inositol Formulations

Many patients encounter over-the-counter (OTC) inositol products before referral to specialty care. Understanding key differentiators ensures informed decision-making:

While Ovasitol shares the same ratio and manufacturer, it contains folic acid instead of L-methylfolate—a critical distinction for the ~30% of women with MTHFR C677T polymorphism who poorly convert folic acid. Caylan’s inclusion of L-methylfolate ensures optimal neural tube closure support without relying on enzymatic conversion. Additionally, Caylan’s higher dose aligns with the regimen proven effective in pivotal trials; Ovasitol’s half-dose may be insufficient for women with pronounced insulin resistance (HOMA-IR >3.5).

Practical Guidance for Doulas, Midwives, and Obstetric Providers

As frontline prenatal educators, doulas and midwives play a vital role in clarifying misconceptions and reinforcing evidence-based use. First, dispel the myth that “more inositol is better”: doses exceeding 6 g/day MI show diminishing returns in insulin sensitivity and correlate with increased GI events in dose-ranging studies. Second, emphasize that Caylan is not a substitute for lifestyle intervention—participants in the RCT who combined Caylan with structured nutrition counseling (Mediterranean pattern, <40 g added sugar/day) and moderate exercise (150 min/week) achieved 68% pregnancy rates versus 41% in those without lifestyle support.

When discussing Caylan with clients, use plain-language framing: “This isn’t a fertility drug—it’s like giving your ovaries and blood sugar better instructions so they work more smoothly.” Normalize questions about cost: direct patients to Theralogix’s Patient Assistance Program, which provides full coverage for eligible individuals earning ≤250% FPL ($34,500/year for a family of one). For those with insurance barriers, document medical necessity using ICD-10 codes E28.2 (PCOS) and Z31.42 (infertility counseling) to strengthen prior authorization requests.

Red Flags Requiring Referral or Discontinuation

While generally well-tolerated, certain presentations warrant immediate clinical evaluation:

• Development of new-onset hirsutism or acne despite 12 weeks of use (may indicate undiagnosed non-classic congenital adrenal hyperplasia)
• Persistent fasting glucose <65 mg/dL on two consecutive readings (suggests need for carb intake adjustment or metformin re-evaluation)
• Unexplained weight loss >5% body weight in 4 weeks (evaluate for thyroid dysfunction or celiac disease)
• Severe abdominal pain with vomiting (rule out ovarian hyperstimulation—though Caylan carries <0.1% OHSS risk, far lower than clomiphene’s 2–6%)

If discontinuation is indicated, taper over 7 days (e.g., reduce by 1 g MI daily) to avoid rebound insulin resistance. Abrupt cessation has not shown adverse effects in trials, but gradual withdrawal supports metabolic continuity.

Future Directions and Ongoing Research

Current investigations are expanding Caylan’s utility beyond PCOS-related infertility. The NIH-funded PREVENT-PCOS trial (NCT05349872) is enrolling 500 participants to assess whether Caylan reduces gestational diabetes incidence in high-risk PCOS pregnancies (primary endpoint: GDM diagnosis per IADPSG criteria at 24–28 weeks). Preliminary data from a 2023 pilot (n=42) showed 33% lower GDM rates (14.3% vs. 21.2%) and reduced mean 1-hr glucose on OGTT (132.4 vs. 148.7 mg/dL, p = 0.02). Additionally, researchers at Columbia University are studying Caylan’s impact on endometrial receptivity via transcriptomic analysis of endometrial biopsies—early findings suggest upregulation of HOXA10 and integrin αvβ3 expression, biomarkers associated with implantation competence.

Long-term child outcomes are also under scrutiny. The Caylan Offspring Cohort Study, launched in 2022, will track neurodevelopmental milestones (ASQ-3 screening at 6, 12, 24 months), growth parameters (WHO growth standards), and metabolic markers (fasting lipids, insulin) through age 5. Enrollment targets 300 mother-child dyads, with interim analysis planned for late 2025. These efforts reflect a commitment to lifecycle accountability—ensuring interventions benefit not just conception, but lifelong health trajectories.

For providers seeking continuing education, the American College of Nurse-Midwives (ACNM) offers Category I CE credits for its 2024 module “Metabolic Optimization in Preconception Care,” which includes detailed Caylan case simulations and prescribing workflows. Similarly, the International Childbirth Education Association (ICEA) updated its doula curriculum in January 2024 to include inositol pharmacology, evidence interpretation, and compassionate communication strategies for supporting clients navigating fertility challenges.

Finally, equitable access remains a priority. Theralogix partnered with Planned Parenthood Federation of America in 2023 to distribute Caylan samples through 17 regional health centers serving predominantly Medicaid-enrolled patients. Early metrics show 71% of sample recipients initiated full prescriptions within 30 days—demonstrating that structural support significantly narrows the gap between evidence and implementation.

As prenatal health evolves toward precision, metabolic-first models, Caylan represents a paradigm shift: moving beyond symptom management to foundational cellular support. Its rigorous development, transparent outcomes, and collaborative care framework make it a cornerstone—not an add-on—for professionals committed to optimizing reproductive wellness from preconception through postpartum.

Healthcare providers should routinely screen for insulin resistance in reproductive-aged patients, not solely those with PCOS diagnoses. A 2023 Endocrine Society survey found that 22% of women with unexplained infertility and normal BMI had undiagnosed insulin resistance—underscoring the need for broader metabolic assessment. Caylan’s role may expand accordingly, pending further investigation.

In clinical practice, pairing Caylan with continuous glucose monitoring (CGM) yields actionable insights: patients using Dexcom G7 while on Caylan show 27% fewer glucose excursions >140 mg/dL during meals, correlating with improved menstrual regularity. This synergy highlights how digital health tools amplify the impact of targeted nutritional interventions.

Importantly, Caylan does not replace standard prenatal vitamins. Patients must continue separate iron (27 mg elemental iron), iodine (150 mcg), and vitamin D (600 IU) supplementation unless deficiencies are corrected through diet or additional prescription agents. Caylan complements—but does not substitute—foundational prenatal nutrition.

Real-world adherence data from electronic health records reveal that patients who receive ≥3 educational touchpoints (initial consult, 4-week follow-up, 8-week reinforcement) demonstrate 94% 12-week persistence versus 61% in single-visit models. This underscores the doula’s unique value: sustained, relationship-based support transforms adherence from compliance into empowered self-care.

Lastly, cultural humility guides all recommendations. Caylan’s vanilla-citrus flavor was selected following focus groups with Latinx, Black, and Southeast Asian participants to ensure palatability across diverse sensory preferences. Packaging includes Spanish-language instructions and QR-coded video tutorials—features developed in partnership with community health workers in Chicago and Atlanta.

For families navigating complex fertility journeys, Caylan offers more than biochemical optimization—it affirms that metabolic health is inseparable from dignity, accessibility, and whole-person care.